Rheumatoid Arthritis Clinical Trials in New York

Showing 521-540 of 3,596 trials

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT05827614

BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). BBI-825 is an oral, potent, selective ribonucleotide reductase (or RNR) small molecule inhibitor. This is a first-in-human, open-label, 2-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with BBI-825 or other select therapies.

Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial Carcinoma+9 more

Boundless Bio, Inc.85 participantsStarted Mar 2023

Los Angeles, California, United States • Santa Monica, California, United States • Denver, Colorado, United States +13 more locations

RECRUITINGPhase 2< 1 mile

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Focal EpilepsyEpilepsyRefractory Focal Epilepsy+3 more

Rapport Therapeutics Inc.30 participantsStarted Dec 2025

Boise, Idaho, United States • Rochester, Minnesota, United States • New York, New York, United States +4 more locations

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Rheumatoid Arthritis Trials in Other Cities

A Randomized Multicenter Study for Isolated Skin Vasculitis

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

One-Time DNA Study for Vasculitis

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Persistent Post-Concussion Symptoms With Convergence Insufficiency

Mind-Body Skills Group for Graduate Students

Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Study of GS-0151 in Participants With Rheumatoid Arthritis

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Learning Study: Improving Vision in Adults With Macular Degeneration

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Other Conditions in New York